Clinical Trial Search

Primary: Hemostatic Efficacy Rating by IEAB — 41; 50; 58; 47 Participants

Primary: Change in Dynamic Imaging Grade of Swallowing Toxicity — 3; 7 Participants — p=0.08

Primary: The Primary Endpoint is Technical Success — 17 Participants

Primary: Virological Response on Treatment Week 6 — 5 Participants

Primary: Oswestry Disability Index — .42; .83; 10.41; .42 score on a scale

Primary: Incidence And Severity Of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 13; 5; 7; 7 Participants

Primary: Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New Gadolinium (Gd) Enhancing T1-hyperintense Lesions — 1.03; 1.39; 0.77; 0.76 lesions — p=0.1673

Primary: Hemoglobin A1c — 8.35; 8.86; 8.75; 8.40 percent of glycated hemoglobin

Primary: NAb Dose Titer in the Convalescent Plasma (CP), Pre-treatment, and Day One in Hospitalized Patients With Documented COVID-19 Infection — 56.7; 390; 413 titer

Primary: Long-term Safety for Engensis Versus Placebo — 10; 8; 1; 2 Participants

Primary: Number of Adverse Events — 13; 13 events

Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (LS-BMD) at Week 52 - Per-Protocol Set — 4.955; 5.099 Percentage change (%)

Primary: Maximum-tolerated Dose of MLN9708. — 4 millligram

Primary: Amount of Blood Products Transfused — 58; 103 milliliter per kilogram (mL/kg)

Primary: Duration of Flare-Free Maintenance Until Onset of First-Flare During the Double Blind (DB) Period — 30; 111 Days — p=0.0034